T2 Biosystems, Inc. (NASDAQ: TTOO) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $12.00 to $3.00. They now have a "hold" rating on the stock.
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
T2 Biosystems shareholders vote to convert $15M CRG debt into equity [Seeking Alpha]
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. [Yahoo! Finance]